The First Evidence Linking Putaminal Dopaminergic Degeneration to Functional Impairment in Parkinson’s Disease

Dopaminergic replacement therapy with levodopa remains the cornerstone of symptomatic treatment in Parkinson’s disease, effectively alleviating motor symptoms—most prominently bradykinesia—arising from dopaminergic degeneration within cortico–basal ganglia networks. However, long-term treatment is frequently complicated by the development of levodopa-induced dyskinesia. Despite extensive research on these phenomena, a comprehensive characterization of how Parkinson’s disease (PD) and levodopa-induced dyskinesia influence motor vigor remains lacking.
In this MEDtalk, Birgitte Liang Chen Thomsen presents novel evidence linking dopaminergic degeneration in the putamen to measurable functional impairment.